Date:9/10/2009

ding statements regarding hopes that BioFoam will reduce the time required to achieve hemostasis during liver resection surgery and reduce the number of complications following surgery, potential distribution timing and uses and applications for BioFoam and timing of enrollment in the feasibility phase of the Company's BioFoam IDE submission. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that BioFoam may not prove safe or effective for its intended uses, that BioFoam may not achieve hemostasis in liver resections or reduce complications following surgery due to any number of factors that we will not be able to identify until further procedures are performed, that BioFoam may not be useful in other future surgical applications, that the Company may not start feasibility phase enrollment in quarter 4 of 2009 due to any number of factors, including unanticipated delays in obtaining FDA and U.S. Department of Defense approval, and that BioFoam development may not result in a commercial product on the time table anticipated, or at all, due to factors beyond our control, including potential lack of acceptance by the medical community. For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's subsequent Form 10-Q filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

    Media Contacts:

    D. Ashley Lee
    Executive Vice President, Chief Financial
    Officer and Chief Operating Officer
    Phone:  770-419-3355

    Dana H
'/>"/>
SOURCE  CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007